Product Introduction

Product Name: Atosiban Product Purity: ≥98% CAS No.: 90779-69-4 Molecular Formula: C₄₃H₆₇N₁₁O₁₂S₂ Molecular Weight: 994.19 Analytical Method: HPLC Active Ingredient: Atosiban Acetate Product Characteristics: White to off-white crystalline powder Product Packaging: Various packaging specifications available (mg, g, kg), customizable  Storage Condition: Recommended to be stored sealed, protected from light, and lyophilized at -20°C Shelf Life: 24 months   Declaration of Use: This product is intended for industrial use or scientific research only.

Products  Description

We specialise in the production of high-purity atosiban active pharmaceutical ingredient (API). Our products are manufactured to the highest pharmaceutical standards, ensuring exceptional quality and consistency in every batch.

We offer flexible packaging solutions ranging from small-scale R&D quantities to commercial batches, enabling direct fulfilment of your specific supply chain requirements from our production site.

Pharmacological Action

Atosiban is a synthetic peptide belonging to the class of tocolytic agents. Its core pharmacological action is the selective inhibition of oxytocin-induced uterine contractions. Unlike other non-specific tocolytics (such as β-adrenergic receptor agonists), Atosiban acts directly on specific receptors in the uterus, resulting in higher targeting precision and favorable tolerability.

Mechanism of Action

The mechanism of action of Atosiban is based on competitive antagonism:

• Targets: It acts as a competitive antagonist for both oxytocin receptors and vasopressin V1a receptors located on the myometrium and decidua.

• Process: By competing with endogenous oxytocin and vasopressin for receptor binding sites, Atosiban effectively blocks the signaling pathways triggered by these hormones. This leads to a decrease in intracellular calcium concentration, thereby inhibiting the contractile activity of uterine smooth muscle cells and achieving the goal of delaying childbirth.

Product Efficacy

As a high-purity active pharmaceutical ingredient (API), the efficacy of Atosiban is realized through its formulated drug products, which deliver the following clinical outcomes:

• Effective Suppression of Uterine Contractions: Rapid onset of action, significantly reducing the frequency and intensity of uterine contractions.

• Delay of Childbirth: Provides crucial time for pregnant women (at 24–33 weeks of gestation) presenting with threatened preterm labor symptoms, allowing for completion of corticosteroid therapy for fetal lung maturation or transfer to a medical center with neonatal intensive care facilities.

Product Applications

This product, as a pharmaceutical API, is primarily used in the following fields:

• Pharmaceutical Industry: Serves as the active component in the manufacture of injectable formulations for the treatment of threatened preterm labor.

• Scientific Research: Used as a reference standard or intervention agent in basic research and drug development within the field of obstetrics and gynecology, particularly in studies related to uterine physiology, mechanisms of preterm birth, and exploration of new therapies.